EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

Laurenz Steiner iD, Lina S Silva-Bermudez iD, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt iD, Patrick Wuchter iD, Wolf-Karsten Hofmann und 1 weitere

European Journal of Haematology · 2026-11 · 117 (5) · 1358-1368

DOI: 10.1111/ejh.70279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 30.07.2026. Verfasst von Laurenz Steiner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Faculty Mannheim, Heidelberg University, Torsten Haferlach Leukemia Diagnostics Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle. Best overall response rate was 76% and did not differ significantly between schedules ( p = 0.38). Median overall survival (OS) was numerically longer with 7d (28.4 months) than with 14d (11.4 months) or > 14d (6.7 months), although unadjusted differences were not significant ( p = 0.23). At cycle level, the 7d schedule was associated with fewer infections and more complication‐free cycles than both longer schedules, while bleeding events were similar. Grade 4 cytopenias and platelet transfusion requirements were also lower with 7d. In an adjusted Cox model, prior HMA exposure, non‐favourable ELN 2024 risk and age ≥ 75 years were associated with inferior OS, whereas the 7d schedule remained associated with improved OS versus > 14d (HR 0.33, p = 0.03). Higher recent grade 4 neutropenia burden was independently associated with inferior OS. These findings suggest that abbreviated VEN exposure may improve tolerability without clear loss of efficacy in AML patients ineligible for intensive chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsHumansAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesFemaleAgedAged, 80 and overDecitabineMaleTreatment OutcomeRetrospective StudiesDrug Administration Schedule

Stichwörter der Autor:innen

acute myeloid leukaemiadose‐adjusted treatmenthypomethylating agentsvenetoclax

Substanzen

venetoclaxAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesDecitabine

Autor:innen und Institutionen

  • Department of Haematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • German Red Cross Blood Service Baden-Württemberg-Hessen, Medical Faculty Mannheim, Institute of Transfusion Medicine and Immunology, Heidelberg University, Mannheim, Germany.
  • Medical Faculty Mannheim, Institute for Clinical Chemistry, Heidelberg University, Mannheim, Germany.

ORCID-Profile: Laurenz Steiner, Lina S Silva-Bermudez, Nanni Schmitt, Patrick Wuchter, Alexander Streuer

Förderung

  • Medical Faculty Mannheim, Heidelberg University
  • Torsten Haferlach Leukemia Diagnostics Foundation

Zitieren

APA

Steiner, L., Silva-Bermudez, L. S., Ghazal, M., Abba, M., Gerhards, C., Metzgeroth, G., Fabarius, A., Klein, S., Kreil, S., Schmitt, N., Wuchter, P., Hofmann, W. K., & Streuer, A. (2026). Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia. European Journal of Haematology, 117(5), 1358-1368. https://doi.org/10.1111/ejh.70279

Vancouver

Steiner L, Silva-Bermudez LS, Ghazal M, Abba M, Gerhards C, Metzgeroth G, et al. Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia. European Journal of Haematology. 2026;117(5):1358-1368. doi:10.1111/ejh.70279

BibTeX
@article{Steiner2026,
  author = {Steiner, Laurenz and Silva-Bermudez, Lina S and Ghazal, Mahmoud and Abba, Mohammed and Gerhards, Catharina and Metzgeroth, Georgia and Fabarius, Alice and Klein, Stefan and Kreil, Sebastian and Schmitt, Nanni and Wuchter, Patrick and Hofmann, Wolf-Karsten and Streuer, Alexander},
  title = {Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {5},
  pages = {1358--1368},
  doi = {10.1111/ejh.70279}
}
Kostenlos starten →